mRNA Vaccines – A Novel Weapon Against Coronavirus
New Technology Attracts Attention
Executive Summary
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
You may also be interested in...
Finance Watch: With Four More IPOs, July May Match Or Exceed June’s 14
Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac has added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties.
Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work
At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.
CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.